Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Agomelatine for depression: expanding the horizons?

Norman TR, Olver JS.

Expert Opin Pharmacother. 2019 Feb 13:1-10. doi: 10.1080/14656566.2019.1574747. [Epub ahead of print]

PMID:
30759026
2.

Problematic medical marijuana, but not all cannabinoids?

Norman TR.

Aust N Z J Psychiatry. 2018 Jan;52(1):95. doi: 10.1177/0004867417722643. Epub 2017 Aug 1. No abstract available.

PMID:
28762285
3.

One-year treatment continuation in patients switched to paliperidone palmitate: a retrospective study.

Hamer J, Norman TR, Kanaan RA.

J Clin Psychiatry. 2014 Nov;75(11):1267-9. doi: 10.4088/JCP.13l08866. No abstract available.

PMID:
25470090
4.

Impairments of spatial working memory and attention following acute psychosocial stress.

Olver JS, Pinney M, Maruff P, Norman TR.

Stress Health. 2015 Apr;31(2):115-23. doi: 10.1002/smi.2533. Epub 2014 Jan 3.

PMID:
24395182
5.

Agomelatine, melatonin and depressive disorder.

Norman TR.

Expert Opin Investig Drugs. 2013 Apr;22(4):407-10. doi: 10.1517/13543784.2013.779668.

PMID:
23484857
6.

The effect of agomelatine on 5HT(2C) receptors in humans: a clinically relevant mechanism?

Norman TR.

Psychopharmacology (Berl). 2012 May;221(1):177-8; author reply 179. doi: 10.1007/s00213-012-2656-6. Epub 2012 Feb 15. No abstract available.

PMID:
22349274
7.

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.

Norman TR, Cranston I, Irons JA, Gabriel C, Dekeyne A, Millan MJ, Mocaër E.

Eur J Pharmacol. 2012 Jan 5;674(1):27-32. doi: 10.1016/j.ejphar.2011.10.010. Epub 2011 Oct 21.

PMID:
22040921
8.

Duloxetine in the acute and continuation treatment of major depressive disorder.

Bochsler L, Olver JS, Norman TR.

Expert Rev Neurother. 2011 Nov;11(11):1525-39. doi: 10.1586/ern.11.133.

PMID:
22014130
9.

The decline and fall of the psychopharmacology empire?

Norman TR.

Aust N Z J Psychiatry. 2011 Nov;45(11):1005. doi: 10.3109/00048674.2011.616857. Epub 2011 Oct 10. No abstract available.

PMID:
21985246
10.

Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder.

Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott AM, Norman TR.

Psychiatry Res. 2010 Jul 30;183(1):85-8. doi: 10.1016/j.pscychresns.2010.04.004. Epub 2010 Jun 9.

PMID:
20538439
11.

Continuation treatment of major depressive disorder: is there a case for duloxetine?

Norman TR, Olver JS.

Drug Des Devel Ther. 2010 Feb 18;4:19-31. Review.

12.

Abnormal dose-response melatonin suppression by light in bipolar type I patients compared with healthy adult subjects.

Hallam KT, Begg DP, Olver JS, Norman TR.

Acta Neuropsychiatr. 2009 Oct;21(5):246-55. doi: 10.1111/j.1601-5215.2009.00416.x.

PMID:
26952772
13.

Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.

Piskulić D, Olver JS, Maruff P, Norman TR.

Hum Psychopharmacol. 2009 Aug;24(6):437-46. doi: 10.1002/hup.1046.

PMID:
19637398
14.

Duloxetine in the treatment of generalized anxiety disorder.

Norman TR, Olver JS.

Neuropsychiatr Dis Treat. 2008 Dec;4(6):1169-80.

15.

Quetiapine augmentation in depressed patients with partial response to antidepressants.

Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR.

Hum Psychopharmacol. 2008 Dec;23(8):653-60. doi: 10.1002/hup.970.

PMID:
18816504
16.

Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder.

Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott A, Norman TR.

J Affect Disord. 2009 Apr;114(1-3):321-6. doi: 10.1016/j.jad.2008.06.020. Epub 2008 Aug 15.

PMID:
18706700
17.

An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers.

Hallam KT, Begg DP, Olver JS, Norman TR.

Hum Psychopharmacol. 2008 Mar;23(2):129-37. doi: 10.1002/hup.913.

PMID:
18172907
18.

Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review.

Piskulic D, Olver JS, Norman TR, Maruff P.

Psychiatry Res. 2007 Mar 30;150(2):111-21. Epub 2007 Feb 12. Review.

PMID:
17292970
19.

Emerging treatments for major depression.

Norman TR, Burrows GD.

Expert Rev Neurother. 2007 Feb;7(2):203-13. Review.

PMID:
17286553
20.

Human embryonic stem cells: a resource for in vitro neuroscience research?

Norman TR.

Neuropsychopharmacology. 2006 Dec;31(12):2571-2. No abstract available.

21.

A double-blind placebo-controlled randomised pilot study of nocturnal melatonin in tracheostomised patients.

Ibrahim MG, Bellomo R, Hart GK, Norman TR, Goldsmith D, Bates S, Egi M.

Crit Care Resusc. 2006 Sep;8(3):187-91.

PMID:
16930101
22.

The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins.

Hallam KT, Olver JS, Chambers V, Begg DP, McGrath C, Norman TR.

Psychoneuroendocrinology. 2006 Aug;31(7):867-75.

PMID:
16769177
23.

Prospects for the treatment of depression.

Norman TR.

Aust N Z J Psychiatry. 2006 May;40(5):394-401. Review.

PMID:
16683964
24.

A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients.

Hong Ng C, Norman TR, Naing KO, Schweitzer I, Kong Wai Ho B, Fan A, Klimidis S.

Int Clin Psychopharmacol. 2006 Mar;21(2):87-92.

PMID:
16421459
25.

Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder.

Hallam KT, Olver JS, Norman TR.

Aust N Z J Psychiatry. 2005 Oct;39(10):947. No abstract available.

PMID:
16168024
26.
27.

Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists.

Begg DP, Hallam KT, Norman TR.

Behav Brain Res. 2005 Jun 20;161(2):286-90. Epub 2005 Mar 31.

PMID:
15922055
28.

Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers.

Hallam KT, Olver JS, Horgan JE, McGrath C, Norman TR.

Int J Neuropsychopharmacol. 2005 Jun;8(2):255-9.

PMID:
15850501
29.

Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers.

Hallam KT, Olver JS, Norman TR.

Neuropsychopharmacology. 2005 Jul;30(7):1400-4.

30.

An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat.

Hallam KT, Horgan JE, McGrath C, Norman TR.

Behav Brain Res. 2004 Aug 31;153(2):481-6.

PMID:
15265646
31.

New formulations of existing antidepressants: advantages in the management of depression.

Norman TR, Olver JS.

CNS Drugs. 2004;18(8):505-20. Review.

PMID:
15182220
32.

Selective effects of acute serotonin and catecholamine depletion on memory in healthy women.

Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ.

J Psychopharmacol. 2004 Mar;18(1):32-40.

PMID:
15107182
33.

Mechanism of action of mirtazapine: dual action or dual effect?

Norman TR.

Aust N Z J Psychiatry. 2004 Apr;38(4):267-9; author reply 269. No abstract available.

PMID:
15038809
34.
35.

The treatment of depression with different formulations of venlafaxine: a comparative analysis.

Olver JS, Burrows GD, Norman TR.

Hum Psychopharmacol. 2004 Jan;19(1):9-16. Review.

PMID:
14716706
36.

Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.

Hallam KT, Olver JS, McGrath C, Norman TR.

Hum Psychopharmacol. 2003 Dec;18(8):619-25.

PMID:
14696021
37.

Brain monoamines and early visual information-processing speed.

Harrison BJ, Olver JS, Norman TR, Nathan PJ.

Int J Neuropsychopharmacol. 2002 Dec;5(4):295-300.

PMID:
12466029
38.

Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers.

Harrison BJ, Olver JS, Norman TR, Nathan PJ.

Hum Psychopharmacol. 2002 Aug;17(6):293-7.

PMID:
12404674
39.

In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes.

Dodd S, Boulton DW, Burrows GD, De Vane CL, Norman TR.

Hum Psychopharmacol. 2001 Oct;16(7):541-544.

PMID:
12404550
40.

Sertraline in paired blood plasma and breast-milk samples from nursing mothers.

Dodd S, Stocky A, Buist A, Burrows GD, Maguire K, Norman TR.

Hum Psychopharmacol. 2000 Jun;15(4):161-264.

PMID:
12404316
41.

Olanzapine excretion in human breast milk: estimation of infant exposure.

Croke S, Buist A, Hackett LP, Ilett KF, Norman TR, Burrows GD.

Int J Neuropsychopharmacol. 2002 Sep;5(3):243-7. doi: 10.1017/S1461145702003012.

PMID:
12366877
42.

Third-generation antidepressants: do they offer advantages over the SSRIs?

Olver JS, Burrows GD, Norman TR.

CNS Drugs. 2001;15(12):941-54. Review.

PMID:
11735614
43.

Sertraline analysis in the plasma of breast-fed infants.

Dodd S, Stocky A, Buist A, Burrows GD, Norman TR.

Aust N Z J Psychiatry. 2001 Aug;35(4):545-6. No abstract available.

PMID:
11531744
44.

The effect of single oral doses of zopiclone on nocturnal melatonin secretion in healthy male volunteers.

Norman TR, Piccolo J, Voudouris N, Burrows GD.

Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):825-33.

PMID:
11383979
45.

Subsensitive melatonin suppression by dim white light: possible biological marker of panic disorder.

Nathan PJ, Burrows GD, Norman TR.

Int J Neuropsychopharmacol. 1998 Dec;1(2):115-120.

PMID:
11281954
46.

Pindolol augmentation of antidepressants: a review and rationale.

Olver JS, Cryan JF, Burrows GD, Norman TR.

Aust N Z J Psychiatry. 2000 Feb;34(1):71-9. Review.

PMID:
11185947
47.

Nefazodone in the breast milk of nursing mothers: a report of two patients.

Dodd S, Maguire KP, Burrows GD, Norman TR.

J Clin Psychopharmacol. 2000 Dec;20(6):717-8. No abstract available.

PMID:
11106156
48.

Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography.

Dodd S, Burrows GD, Norman TR.

J Chromatogr B Biomed Sci Appl. 2000 Oct 10;748(2):439-43.

PMID:
11087086
49.

Antidepressants and breast-feeding: a review of the literature.

Dodd S, Buist A, Norman TR.

Paediatr Drugs. 2000 May-Jun;2(3):183-92. Review.

PMID:
10937469
50.

Acute increases in night-time plasma melatonin levels following a period of meditation.

Tooley GA, Armstrong SM, Norman TR, Sali A.

Biol Psychol. 2000 May;53(1):69-78.

PMID:
10876066

Supplemental Content

Loading ...
Support Center